Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411099 | 1.00 | PTPN1 (1.00) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL11482012 | 0.92 | PTPN1 (0.84) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL15114347 | 0.88 | PTPN1 (0.78) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL8011026 | 0.85 | PTPN1 (0.74) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL27529851 | 0.85 | PTPN1 (0.73) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL4333412 | 0.84 | PTPN1 (0.71) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL1974978 | 0.83 | PTPN1 (0.71) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL29489791 | 0.83 | PTPN1 (0.71) | PTPN1CES2CES1SMN1; SMN2KDM4E | |
| SCHEMBL203507 | 0.82 | PTPN1 (0.70) | PTPN1GSK3BCYP3A4 | |
| SCHEMBL4328129 | 0.82 | PTPN1 (0.69) | PTPN1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598780-A | Aggregation-induced emission naphthyl benzenesulfonyl ethanone and preparation thereof | 内蒙古工业大学 | 2024-09-06 | — | — | CN | claimed |
| CN-115368346-B | 1, 4-benzodioxane-benzimidazole salt compound and synthesis method and application thereof | 曲靖师范学院 | 2024-04-09 | — | — | CN | claimed |
| EP-3959200-B1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | ANADOLU UNIV (TR) | 2024-03-20 | — | — | EP | claimed |
| EP-3958980-B1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU UNIV (TR) | 2023-11-15 | — | — | EP | claimed |
| CN-115368346-A | 1, 4-benzodioxan-benzimidazole salt compound and synthesis method and application thereof | 曲靖师范学院 | 2022-11-22 | — | — | CN | claimed |
| EP-3959200-A1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| WO-2022005414-A1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | ANADOLU UNIVERSITESI (TR) | 2022-01-06 | — | — | WO | claimed |
| WO-2021257020-A1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU ÜNİVERSİTESİ (TR) | 2021-12-23 | — | — | WO | claimed |
| US-10092786-B2 | Fire extinguishing composition comprising aldoketones compound | XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) | 2018-10-09 | — | — | US | claimed |
| US-20160332016-A1 | Fire Extinguishing Composition Comprising Aldoketones Compound | NANO FIRE, LLC | 2016-11-17 | — | — | US | claimed |
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | claimed |
| EP-2280956-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | claimed |
| US-4328356-A | Process for preparing esters of arylacetic acids from alpha-halo-alkylarylketones | MONTEDISON S.P.A. (IT) | 1982-05-04 | — | — | US | claimed |
| JP-7159992-A | — | — | None | — | — | JP | disclosed |
| JP-8006251-A | — | — | None | — | — | JP | disclosed |
| EP-4446327-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-09-24 | — | — | EP | disclosed |
| US-4080506-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-03-21 | — | — | US | disclosed |
| US-4079062-A | ANTIMICROBIAL, PLANT GROWTH REGULATORS; 1-(B-ARYL)ETHYL-1H-1,2,4-TRIAZOLE KETALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-03-14 | — | — | US | disclosed |
| US-3979440-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | CYP51A1, KMO, TALDO1 | PTPN1 4327/4885CES2 663/4885CES1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.